IDEC Pharmaceuticals focuses on the commercialization and development of targeted therapies for the treatment of cancer and autoimmune diseases.
Genetics Institute developed pharmaceuticals based on leading edge functional genomics technologies and proprietary disease models to treat a wide variety of human disease conditions.
Fate Therapeutics is pioneering the emerging field of renewal therapies by redirecting the fate of the body’s adult stem cells to intervene in human disease, aberrant physiology or damaged tissue with “renewed” cellular health.
Coley Pharmaceutical Group discovers, develops and commercializes a new class of drugs that stimulate the human immune system to treat and prevent cancers, asthma, allergy and infectious diseases.
Centocor is an integrated biopharmaceutical company developing monoclonal antibody-based products for cardiovascular and autoimmune diseases, cancer and inflammation.
Celladon is developing a unique therapeutics platform to treat severe heart failure.
Adnexus Theraputics is a developer of a class of protein therapeutics in Phase 1 trials of its lead product candidate and with a pipeline of other products in preclinical research across multiple therapeutic areas.
Acceleron is a biopharmaceutical company developing drugs for important unmet medical needs through proprietary approaches that exploit the therapeutic potential of a large family of growth and differentiation factors.